百普赛斯 (301080)
ACROBIOSYSTEMS CO.,LTD.
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 16717.77
- Circulating A-Shares(W): 12599.83
- Earnings Per Share(RMB): 0.7914
- Net Assets Per Share(RMB): 15.7432
- Operating Revenue(W RMB): 61298.54
- Total Profit(W RMB): 13820.61
- Net Profit Attributable to Parent(W RMB): 13242.64
- Net Profit Growth Rate(%): 58.61
- Weighted Return on Equity(%): 5.0600
- Operating Cash Flow Per Share(RMB): 1.0550
- Undistributed Profit Per Share(RMB): 2.2002
- Capital Reserve Per Share(RMB): 12.2180
2. Main Business
The main business covers:
- Providing key biological reagent products and technical services such as recombinant proteins and antibodies.
3. Company Basic Information
- Company Name: Beijing Acrobiosystems Co., Ltd.
- Listing Date: 2021-10-18
- Industry: Research and Experimental Development
- Address: 4th Floor, Building 4 & 5, No. 8 Hongda North Road, Beijing Economic-Technological Development Area, Daxing District, Beijing, China
- Website: www.acrobiosystems.cn
- Company Profile: On May 20, 2020, Acrobiosystems Limited convened a shareholders' meeting and decided to establish a joint stock company by way of overall change. On June 6, 2020, all shareholders of Acrobiosystems Limited, as promoters, convened the inaugural meeting and the first extraordinary general meeting of Acrobiosystems in 2020. According to the "Appraisal Report" issued by Zhongshui Zhiyuan Asset Appraisal Co., Ltd. (Zhongshui Zhiyuan Ping Bao Zi [2020] No. 020229), the appraised net assets of Acrobiosystems Limited as of March 31, 2020 were 135.8723 million yuan. According to the "Audit Report" issued by Rongcheng Certified Public Accountants (Rongcheng Shen Zi [2020] 100Z1050), the audited book value of net assets of Acrobiosystems Limited as of March 31, 2020, amounting to 115.8240 million yuan, was converted into 60 million shares, with the remainder credited to capital reserve. The capital contribution involved in the establishment of the joint stock company was verified by the "Capital Verification Report" issued by Rongcheng Certified Public Accountants on June 6, 2020 (Rongcheng Yan Zi [2020] 100Z0046). On June 9, 2020, the company obtained the "Business License" for the joint stock company issued by the Beijing Economic-Technological Development Area Market Supervision Administration, with the Unified Social Credit Code of 911103025604366893.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Anyi Acrobiosystems Enterprise Management Consulting Partnership (Limited Partnership) | General Legal Person | 1356.10 | 10.71 |
| 2 | Hong Kong Securities Clearing Company Ltd. | Northbound Funds | 1355.58 | 10.70 |
| 3 | China Europe Healthcare Hybrid Securities Investment Fund Class A | Fund | 599.44 | 4.73 |
| 4 | Nanjing High-Tech Xinjun Growth Phase I Equity Investment Partnership (Limited Partnership) | General Legal Person | 251.87 | 1.99 |
| 5 | China Europe Medical Innovation Equity Securities Investment Fund Class A | Fund | 206.14 | 1.63 |
| 6 | Anyi Acrobiosystems Jiale Enterprise Management Consulting Partnership (Limited Partnership) | General Legal Person | 201.04 | 1.59 |
| 7 | GF Steady Return Hybrid Securities Investment Fund Class A | Fund | 185.79 | 1.47 |
| 8 | Yuansin Yongfeng Pharmaceutical Health Hybrid Securities Investment Fund Class A | Fund | 50.01 | 0.39 |
| 9 | Yuansin Yongfeng Juyou Equity Securities Investment Fund Class A | Fund | 37.41 | 0.30 |
| 10 | China Merchants Fengyun Hybrid Securities Investment Fund Class A | Fund | 23.80 | 0.19 |
5. Concept Sectors
- Immunotherapy
- Artificial Intelligence
- Margin Trading & Securities Lending
- High-Performance Stocks
- Shareholder Reduction
- Specialized, Refined, Distinctive, and Innovative SMEs
- ChiNext Growth
- ChiNext Pharmaceuticals
- ChiNext 200
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information